|
Amgen heart failure drug deal is good news — but little more — for Cytokinetics
San Francisco Business Times (blog) Thousand Oaks-based Amgen, meanwhile, received U.S. commercial rights to Servier’s chronic heart failure drug ivabradine, which is approved in Europe, and an exclusive option to develop and commercialize Servier’s Phase II heart failure drug S-38844 in … |
Surrey man turns to India for transplant donor after years waiting in BC (w … – Vancouver Desi
Vancouver Desi |
Surrey man turns to India for transplant donor after years waiting in BC (w …
Vancouver Desi The only thing that could make his life “completely normal again” is a kidney transplant — a South Asian donor his most-likely match, but with incredibly low organ donation rates among B.C.’s South Asian community, Thind has been told he could wait up … |
GSK taps UK firm for 'beyond antibodies' drug technology – Yahoo! News
|
GSK taps UK firm for ‘beyond antibodies‘ drug technology
Yahoo! News LONDON (Reuters) – GlaxoSmithKline (Other OTC: GLAXF – news) plans to exploit new technology from private British biotech company Immunocore to develop next-generation drugs against cancer that fight tumours in ways antibody-based drugs cannot. |
CSACI position statement: safety of topical calcineurin inhibitors in the … – 7thSpace Interactive (press release)
CSACI position statement: safety of topical calcineurin inhibitors in the …7thSpace Interactive (press release)Utilizing topical calcineurin inhibitors (TCIs) for the treatment of AD not responsive to high-potency corticosteroids, or low-potency cort…
'Dead' patient opened eyes minutes before NY docs were due to harvest organs … – New York Post
|
‘Dead’ patient opened eyes minutes before NY docs were due to harvest organs …
New York Post The hospital submitted a plan to correct the problems to the state health department, which ordered it to hire a consulting neurologist to teach staff how to diagnose brain death and a consultant to review the hospital’s quality assurance program. U.S … |
Air pollution boosts risk of lung cancer, heart failure – Channel News Asia
Air pollution boosts risk of lung cancer, heart failureChannel News AsiaA separate report said short-term surge in these particles or other gas pollutants in the air also increases the risk of heart failure. European epidemiologists said they had found…
AIIMS to start 75-bed hospital – Times of India
|
AIIMS to start 75-bed hospital
Times of India Besides, it has specialized afternoon clinics for sleep disorder, lung, head and neck cancer, infertility, orthodentistry. It also runs a daycare facility for cancer patients. “We are ahead of other AIIMS clones in starting the afternoon clinics though … |
Conjoined twins from MP leave AIIMS to lead separate lives – Indian Express
The Hindu |
Conjoined twins from MP leave AIIMS to lead separate lives
Indian Express Dr M Bajpai, HoD, paediatric surgery department, said, “Their lower chest and upper abdomen — including the chest bone — were joined, and they had a common liver. Thankfully, the hearts were separate, with their own respective blood supplies … Twins who shared liver survive 8-hour surgeryHindustan Times Joined at birth, twins can now lead separate livesTimes of India Conjoined twins from Madhya Pradesh successfully separated at AIIMSIndia.Com Health Calcutta Telegraph –The Hindu –India Today all 9 news articles » |
Traders association holds blood donation camp – Hindustan Times
Traders association holds blood donation campHindustan TimesThe Gandhi Nagar Traders Manufacturer Association in collaboration with Zindagi Live Foundation organised a voluntary blood-donation camp at Rajkarni Laxmi Naryan Mandir at Gandhi Nagar here o…
GSK taps UK firm for 'beyond antibodies' drug technology – WKZO
Economic Times |
GSK taps UK firm for ‘beyond antibodies‘ drug technology
WKZO GSK taps UK firm for ‘beyond antibodies‘ drug technology. Tuesday, July 09, 2013 7:51 p.m. EDT. By P.J. Huffstutter. LONDON (Reuters) – GlaxoSmithKline plans to exploit new technology from private British biotech company Immunocore to develop … Cutting Edge Cancer Therapy From Immunocore Receives $212M In Funding …Medical Daily |